Citigroup Inc Tenaya Therapeutics, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Tenaya Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 40,107 shares of TNYA stock, worth $95,454. This represents 0.0% of its overall portfolio holdings.

Number of Shares

40,107

Previous 12,314 225.7%

Holding current value

$95,454

Previous $38,000 102.63%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$1.93 - $3.99 $53,640 - $110,894	27,793 Added 225.7%	40,107 $77,000
Q2 2024 Aug 12, 2024	SELL	$2.72 - $4.99 $4,882 - $8,957	-1,795 Reduced 12.72%	12,314 $38,000
Q1 2024 May 10, 2024	BUY	$2.88 - $6.8 $21,044 - $49,687	7,307 Added 107.42%	14,109 $73,000
Q4 2023 Feb 09, 2024	BUY	$1.73 - $3.39 $10,933 - $21,424	6,320 Added 1311.2%	6,802 $22,000
Q3 2023 Nov 09, 2023	SELL	$2.55 - $5.65 $34,700 - $76,885	-13,608 Reduced 96.58%	482 $1,000
Q2 2023 Aug 10, 2023	BUY	$2.64 - $7.64 $36,038 - $104,293	13,651 Added 3109.57%	14,090 $82,000
Q1 2023 May 11, 2023	SELL	$1.92 - $3.59 $480 - $897	-250 Reduced 36.28%	439 $1,000
Q4 2022 Feb 09, 2023	SELL	$1.68 - $3.19 $270,206 - $513,070	-160,837 Reduced 99.57%	689 $1,000
Q3 2022 Nov 10, 2022	BUY	$2.9 - $5.88 $460,540 - $933,785	158,807 Added 5840.64%	161,526 $468,000
Q2 2022 Aug 10, 2022	BUY	$5.01 - $14.12 $3,587 - $10,109	716 Added 35.75%	2,719 $15,000
Q1 2022 May 12, 2022	SELL	$9.41 - $19.3 $26,517 - $54,387	-2,818 Reduced 58.45%	2,003 $24,000
Q4 2021 Feb 10, 2022	BUY	$18.41 - $29.58 $59,501 - $95,602	3,232 Added 203.4%	4,821 $91,000
Q3 2021 Nov 10, 2021	BUY	$15.35 - $26.66 $24,391 - $42,362	1,589 New	1,589 $33,000

Others Institutions Holding TNYA

# of Institutions

Shares Held

56.3M

Call Options Held

900

Put Options Held

400

View Full List

About Tenaya Therapeutics, Inc.

Ticker TNYA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,364,700
Market Cap $98.4M
Description
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hyp...

More about TNYA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account